Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

(Moderate)

(Very Positive)

Rhea-AI Summary

Serina Therapeutics (NYSE American: SER) announced that its management will participate in the BTIG Virtual Biotechnology Conference, held July 28-29, 2026, and will host virtual one-on-one investor meetings on Wednesday, July 29, 2026, arranged through BTIG representatives.

The company highlights its proprietary POZ Platform, a poly(2-oxazoline)-based polymer technology designed to optimize drug loading and controlled release for subcutaneous delivery, including a non-exclusive license agreement with Pfizer for use in lipid nanoparticle formulations. Serina also features SER-252, an investigational POZ-apomorphine therapy aiming to provide continuous dopaminergic stimulation in Parkinson’s disease.

News Market Reaction – SER

-0.96%

1 alert

-0.96% Session close to close

$32.54M Market Cap

0.1x Rel. Volume

In the Jul 24 session, SER declined 0.96%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Insider filings showed Net Buying over the past 90 days, adding a platform-level ownership signal to...

Analysis

Insider filings showed Net Buying over the past 90 days, adding a platform-level ownership signal to this conference announcement. The active S-3 covers resale registration, while moderate short positioning is a risk to monitor.

Key Figures

Conference dates: July 28-29, 2026 Investor meeting date: Wednesday, July 29, 2026

2 metrics

Conference dates July 28-29, 2026 BTIG Virtual Biotechnology Conference

Investor meeting date Wednesday, July 29, 2026 Virtual one-on-one investor meetings

Historical Context

5 past events · Latest: Jul 23 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 23	Trial enrollment update	Positive	+0.9%	Completed enrollment and dosing in Cohort 1 ahead of prior guidance
Jul 22	Board appointment	Neutral	+0.9%	Appointed Farrell Simon to the board and outlined SER-252 trial design
Jul 09	Trial dosing update	Positive	+10.0%	Completed sentinel dosing and received continued dosing recommendation
May 14	Quarterly earnings report	Negative	-4.7%	Reported operating expenses, net loss, cash balance, and financing proceeds
Apr 07	LNP presentation	Negative	-3.3%	Presented POZ-lipid study results and disclosed no antibody response

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical reactions were mixed, with positive trial and board updates alongside negative earnings and presentation reactions.

Key Terms

pharmacokinetic profiles, poly(2-oxazoline), lipid nanoparticle, continuous dopaminergic stimulation, +1 more

5 terms

pharmacokinetic profiles medical

"limited by pharmacokinetic profiles that can include toxicity"

Measurements and charts that describe how a drug moves through and leaves the body over time — including how quickly it is absorbed, how it spreads to tissues, how the body breaks it down, and how it is excreted. Think of it like a timeline showing blood levels after taking a pill, with key numbers such as peak concentration, total exposure, and half‑life. Investors use these profiles to gauge a drug’s dosing needs, safety window, development complexity, and how it compares to competing medicines.

poly(2-oxazoline) technical

"a synthetic, water-soluble, low viscosity polymer called poly(2-oxazoline)"

A poly(2-oxazoline) is a family of synthetic, water‑soluble polymers made by linking 2‑oxazoline building blocks into long chains; their length and chemical side groups can be tuned to change flexibility, solubility and surface behavior. Think of them as customizable microscopic coatings or sleeves that can make drug molecules or surfaces more stable, more soluble, or less visible to the immune system. Investors watch them because they are used in drug delivery, biologic formulation and medical-device coatings, so their properties can influence product performance, manufacturing choices and regulatory review.

lipid nanoparticle technical

"use Serina’s POZ polymer technology in lipid nanoparticle"

A lipid nanoparticle is a tiny, fat‑based microscopic shell that carries and protects delicate molecules (like RNA or drugs) and helps them enter cells, similar to a microscopic delivery bubble. It matters to investors because this delivery method can make new therapies and vaccines possible or more effective, but also affects manufacturing complexity, scalability, regulatory review and cost — all of which influence a biotech company’s commercial prospects.

continuous dopaminergic stimulation medical

"designed to provide continuous dopaminergic stimulation (CDS)"

Continuous dopaminergic stimulation is a medical approach that delivers steady, sustained levels of dopamine or dopamine‑like medication to the brain—using long‑acting pills, patches, pumps, or implants—to avoid the highs and lows caused by intermittent dosing. For investors, it matters because therapies and devices built on this concept target more consistent symptom control and fewer treatment complications, which affects clinical trial outcomes, regulatory review, adoption by clinicians and patients, and the commercial potential of related products.

antibody-based drug conjugates medical

"small molecules, RNA-based therapeutics and antibody-based drug conjugates"

Antibody-based drug conjugates are targeted medicines made by linking a disease-fighting payload, often a toxic drug, to an antibody that recognizes specific markers on cells. Like a guided missile carrying a warhead to a precise target, they aim to deliver the active drug directly to diseased cells while limiting exposure elsewhere; investors watch them because their design can affect clinical success, manufacturing complexity, regulatory review, and potential market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

07/24/2026 - 06:00 AM

HUNTSVILLE, Ala., July 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced that management will participate in the BTIG Virtual Biotechnology Conference, taking place July 28-29, 2026.

Management will hold virtual one-on-one investor meetings on Wednesday, July 29, 2026. Please contact your BTIG representative to request a meeting.

About the POZ Platform™

Serina’s proprietary POZ technology is based on a synthetic, water-soluble, low viscosity polymer called poly(2-oxazoline). The POZ platform is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. The therapeutic agents in Serina’s product candidates are typically well-understood and marketed drugs that are effective but limited by pharmacokinetic profiles that can include toxicity, side effects and short half-life.

Serina believes that by using POZ technology, drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.

Serina’s POZ platform delivery technology has potential for use across a broad range of payloads and indications. Serina intends to advance additional applications of the POZ platform via out-licensing, co-development, or other partnership arrangements, including the non-exclusive license agreement with Pfizer Inc. to use Serina’s POZ polymer technology in lipid nanoparticle (LNP) drug delivery formulations.

About SER-252 (POZ-apomorphine)

SER-252 is an investigational apomorphine therapy developed with Serina’s POZ platform and designed to provide continuous dopaminergic stimulation (CDS). CDS has been shown to reduce the severity of levodopa-related motor complications (dyskinesia) in Parkinson’s disease. Preclinical studies support the potential of SER-252 to provide CDS without skin reactions.

About Serina Therapeutics

Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform^™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology. For more information, please visit https://serinatx.com.

For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630

FAQ

What is Serina Therapeutics (NYSE American: SER) doing at the BTIG Virtual Biotechnology Conference 2026?

Serina Therapeutics is participating in the BTIG Virtual Biotechnology Conference 2026 and holding virtual one-on-one investor meetings on July 29, 2026. According to Serina, investors can request meetings through their BTIG representatives, providing direct access to management to discuss the POZ Platform and pipeline.

When will Serina Therapeutics (SER) hold investor meetings at the BTIG Virtual Biotechnology Conference?

Serina Therapeutics will hold virtual one-on-one investor meetings on Wednesday, July 29, 2026, during the BTIG Virtual Biotechnology Conference. According to Serina, interested investors should contact their BTIG representative to schedule meetings and engage with management about the company’s clinical programs and POZ technology.

What is Serina Therapeutics’ POZ Platform and how does it work for SER investors to understand?

Serina’s POZ Platform uses a synthetic, water-soluble poly(2-oxazoline) polymer to enable controlled drug loading and precise release via subcutaneous injection. According to Serina, it aims to maintain more stable blood levels of known drugs, potentially improving tolerability and addressing toxicity, side effects, and short half-life limitations.

What is SER-252 (POZ-apomorphine) in Serina Therapeutics’ pipeline for Parkinson’s disease?

SER-252 is an investigational apomorphine therapy developed with Serina’s POZ Platform and designed to provide continuous dopaminergic stimulation. According to Serina, continuous stimulation has been shown to reduce levodopa-related motor complications, and preclinical studies support the potential for SER-252 to provide this without skin reactions.

Does Serina Therapeutics (SER) have any partnership involving its POZ polymer technology?

Serina Therapeutics has a non-exclusive license agreement with Pfizer to use its POZ polymer technology in lipid nanoparticle drug delivery formulations. According to Serina, it also plans to advance additional POZ applications through out-licensing, co-development, or other partnership arrangements across a range of therapeutic indications.